Cargando…
Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related death in many countries. Approximately half of the patients with non-small cell lung cancer have advanced disease and systemic chemotherapy, especially platinum-based doublets, is currently the standard treatment. Several trials have recently indica...
Autores principales: | Hayashi, Hidetoshi, Kurata, Takayasu, Nakagawa, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117632/ https://www.ncbi.nlm.nih.gov/pubmed/21695043 http://dx.doi.org/10.4137/CMO.S6252 |
Ejemplares similares
-
An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
por: Patil, Pradnya Dinkar, et al.
Publicado: (2019) -
Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021) -
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer
por: Kurata, T, et al.
Publicado: (2004) -
Biomarker testing for personalized, first-line therapy in advanced
nonsquamous non-small cell lung cancer patients in the real world setting in
Japan: a retrospective, multicenter, observational study (the BRAVE
study)
por: Shimizu, Junichi, et al.
Publicado: (2020) -
Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)